Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherPractice

Pharmacologic treatment of alcohol use disorder

Caitlin R. Finley, Carly Rumley and Christina S. Korownyk
Canadian Family Physician August 2020, 66 (8) 583;
Caitlin R. Finley
Medical student, at the University of Alberta in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carly Rumley
Second-year family medicine resident, at the University of Alberta in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina S. Korownyk
Family physician and Associate Professor in the Department of Family Medicine, at the University of Alberta in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Clinical question

Which Health Canada–approved pharmacologic treatments are effective for alcohol use disorder (AUD)?

Bottom line

Both acamprosate and naltrexone show benefit for alcohol abstinence compared with placebo. For every 12 patients treated with acamprosate, and every 20 patients treated with naltrexone, 1 fewer patient returns to drinking compared with placebo after 12 to 52 weeks. For harm reduction, naltrexone can reduce return to heavy drinking for 1 of every 13 patients.

Evidence

Results are statistically significant unless noted.

  • In a systematic review of RCTs of 12- to 52-week treatments, most included supportive therapy and required detoxification. Results versus placebo were as follows1:

    • -Return to any drinking:

      • — For acamprosate (16 RCTs, N = 4847), the most common dose was 666 mg 3 times per day. The rate was 76% versus 83% for placebo (number needed to treat [NNT] of 12).

      • — For 50 mg of oral naltrexone daily (16 RCTs, N = 2347), the rate was 63% versus 68% with placebo (NNT = 20).

      • — There was no difference with injectable naltrexone (2 RCTs, N = 939) or disulfiram (2 RCTs, N = 492).

    • -Return to heavy drinking:

    • — For 50 mg of oral naltrexone daily (19 RCTs, N = 2875), the rate was 46% versus 54% with placebo (NNT = 13).

    • — There was no difference with acamprosate (7 RCTs, N = 2496).

  • Earlier systematic reviews of acamprosate2 and naltrexone3 reported similar results.

  • Evidence is insufficient or finds no benefit for acamprosate or naltrexone on mortality1,4,5 or quality of life.1

  • The most common adverse effects for naltrexone3,5 were nausea (26% vs 16% for placebo, number needed to harm [NNH] of 10) and sleepiness (21% vs 16% for placebo, NNH = 20). For acamprosate,4 the incidence of diarrhea (16% vs 10% for placebo, NNH = 17) decreases after the first 4 weeks of treatment.

Context

  • Guidelines suggest that first-line pharmacotherapy include acamprosate for abstinence or naltrexone for reduced drinking or abstinence, and give practical prescribing tips.6

  • Limited evidence has evaluated as-needed naltrexone. It might reduce alcohol consumption when used as cravings arise or before expected drinking.7

  • Supportive interventions, including brief interventions in primary care, might benefit 1 in 10 individuals with excessive alcohol intake.8

  • If patients do not respond to approved medications, a trial of alternative medications (eg, topiramate, gabapentin) might be reasonable.6

Implementation

In Canada, alcohol use is linked to about 8% of all deaths.6 Hospitalizations for AUD have increased over time, as has the number of patients presenting to primary care for alcohol-attributable diseases.9 Only limited numbers of individuals with AUD are offered treatment.6 The existence of multiple medications with evidence of benefit provides options for shared, informed decision making with patients. While abstinence is a laudable goal, reductions in return to heavy drinking or reduced heavy drinking days are also associated with improved outcomes.10

Notes

Tools for Practice articles in Canadian Family Physician are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in Canadian Family Physician are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice{at}cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.

Footnotes

  • Competing interests

    None declared

  • The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

  • This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to www.cfp.ca and click on the Mainpro+ link.

  • La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro d’août 2020 à la page e216.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Jonas DE,
    2. Amick HR,
    3. Feltner C,
    4. Bobashev G,
    5. Thomas K,
    6. Wines R,
    7. et al
    . Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014;311(18):1889-900.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Rösner S,
    2. Hackl-Herrwerth A,
    3. Leucht S,
    4. Lehert P,
    5. Vecchi S,
    6. Soyka M
    . Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010;(9):CD004332.
  3. 3.↵
    1. Rösner S,
    2. Hackl-Herrwerth A,
    3. Leucht S,
    4. Vecchi S,
    5. Srisurapanont M,
    6. Soyka M
    . Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010;(12):CD001867.
  4. 4.↵
    1. Rosenthal RN,
    2. Gage A,
    3. Perhach JL,
    4. Goodman AM
    . Acamprosate: safety and tolerability in the treatment of alcohol dependence. J Addict Med 2008;2(1):40-50.
    OpenUrlPubMed
  5. 5.↵
    1. Bolton M,
    2. Hodkinson A,
    3. Boda S,
    4. Mould A,
    5. Panagioti M,
    6. Rhodes S,
    7. et al
    . Serious adverse events reported in placebo randomized controlled trials of oral naltrexone: a systematic review and meta-analysis. BMC Med 2019;(17):10.
  6. 6.↵
    1. British Columbia Centre on Substance Use, BC Ministry of Health, BC Ministry of Mental Health and Addictions
    . Provincial guideline for the clinical management of high-risk drinking and alcohol use disorder. Vancouver, BC: British Columbia Centre on Substance Use; 2019.
  7. 7.↵
    1. Heinälä P,
    2. Alho H,
    3. Kiianmaa K,
    4. Lönngvist J,
    5. Kuoppasalmi K,
    6. Sinclair JD
    . Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 2001;21(3):287-92.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Salvalaggio G,
    2. Korownyk C
    . Tools for Practice #134. Edmonton, AB: Alberta College of Family Physicians; 2015. Getting patients to drink less—are words mightier than drink?
  9. 9.↵
    1. Slaunwhite AK,
    2. Macdonald S
    . Primary health care utilization for alcohol-attributed diseases in British Columbia Canada 2001–2011. BMC Fam Pract 2015;16:34.
    OpenUrl
  10. 10.↵
    1. Witkiewitz K,
    2. Roos CR,
    3. Pearson MR,
    4. Hallgren KA,
    5. Maisto SA,
    6. Kirouac M,
    7. et al
    . How much is too much? Patterns of drinking during alcohol treatment and associations with post-treatment outcomes across three alcohol clinical trials. J Stud Alcohol Drugs 2017;78(1):59-69.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Family Physician: 66 (8)
Canadian Family Physician
Vol. 66, Issue 8
1 Aug 2020
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacologic treatment of alcohol use disorder
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pharmacologic treatment of alcohol use disorder
Caitlin R. Finley, Carly Rumley, Christina S. Korownyk
Canadian Family Physician Aug 2020, 66 (8) 583;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Pharmacologic treatment of alcohol use disorder
Caitlin R. Finley, Carly Rumley, Christina S. Korownyk
Canadian Family Physician Aug 2020, 66 (8) 583;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Bottom line
    • Evidence
    • Context
    • Implementation
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Traitement pharmacologique du trouble de consommation d’alcool
  • PubMed
  • Google Scholar

Cited By...

  • Gabapentin for alcohol use disorder
  • Google Scholar

More in this TOC Section

Practice

  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
Show more Practice

Tools for Practice

  • Budesonide bests COVID-19
  • Exercise for peripheral artery disease
  • Compression stockings for recurrent cellulitis
Show more Tools for Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2022 by The College of Family Physicians of Canada

Powered by HighWire